{
  "event_id": "0f7f89d3085e",
  "ticker": "SNY",
  "company_name": "Sanofi",
  "drug_name": "Dupixent dupilumab",
  "pdufa_date": "20240112",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:SOLO 1/2, LIBERTY AD Phase 3 (2017)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.477005",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Atopic dermatitis, asthma, CRSwNP",
    "source": "websearch:SOLO 1/2, LIBERTY AD Phase 3 (2017)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.477006",
    "error": null
  },
  "generic_name": {
    "status": "not_searched",
    "value": null,
    "source": null,
    "confidence": 0.0,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "_reset_reason": "Was inferred from: brand_to_generic_map",
    "_reset_at": "2026-01-09T23:49:24.204703"
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Immunology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.082653",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "derived_from_result",
    "confidence": 0.95,
    "tier": 1,
    "searched_sources": [
      "result_field"
    ],
    "last_searched": null,
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:SOLO 1/2, LIBERTY AD Phase 3 (2017)",
    "confidence": 0.95,
    "evidence": [
      "SOLO 1/2, LIBERTY AD Phase 3 (2017)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.476990",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "<0.0001",
    "source": "websearch:SOLO 1/2, LIBERTY AD Phase 3 (2017)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.476998",
    "error": null
  },
  "p_value_numeric": 0.0001,
  "effect_size": {
    "status": "found",
    "value": "IGA 0/1: 36-38% vs 8-10%; EASI-75: 51% vs 15%",
    "source": "websearch:SOLO 1/2, LIBERTY AD Phase 3 (2017)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.477000",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis"
  ],
  "nct_ids": [
    "NCT02277743"
  ],
  "enrollment": {
    "count": 671,
    "type": "ACTUAL",
    "nct_id": "NCT02277743",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:30:34.009935"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": false,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:19:33.079430",
  "enriched_at": "2026-01-11T20:16:34.091060",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "845a7046fd4c",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": false,
    "priority_review": true,
    "orphan_drug": false,
    "accelerated_approval": false
  },
  "mechanism_of_action": "IL-4/IL-13 inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -729,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:42.094223",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:18.848904"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:18.848912"
  },
  "breakthrough_therapy": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA grants Dupixent® (dupilumab) Breakthrough Therapy ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:18.954677",
    "search_status": "FOUND"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Dupixent® (dupilumab) Approved in the U.S. as the Only"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:20.170159",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:21.358056",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:27.580476",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:34.091044",
    "search_status": "CONFIRMED_NONE"
  }
}